ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CPMD Cannapharmarx Inc (PK)

0.0146
0.0026 (21.67%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cannapharmarx Inc (PK) USOTC:CPMD OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0026 21.67% 0.0146 0.014 0.0154 0.0155 0.012 0.012 193,321 18:40:43

Current Report Filing (8-k)

16/02/2022 9:02pm

Edgar (US Regulatory)


0001081938 false 0001081938 2022-02-14 2022-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

U.S. SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

February 14, 2022

 

Cannapharmarx, Inc.

(Exact name of small business issuer as specified in its charter)

 

Delaware 333-251016 27-4635140

(State or other jurisdiction of incorporation)

 

(Commission File Number) (IRS Employer ID No.)

 

Suite 3600

888-3rd Street SW

Calgary, Alberta, Canada T2P5C5

(Address of principal executive offices)

 

(949) 652-6838

(Issuer’s Telephone Number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock CPMD OTC Pink Sheets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Item 7.01Regulation FD Disclosure

 

Attached is a copy of a press release being issued by the Company relating to the Letter of Intent, a copy of which is attached as Exhibit 99.6 and is hereby incorporated.

 

Item 9.01.Financial Statements and Exhibits.

 

(c) Exhibits.

 

Number Exhibit
99.6 Press Release
104 Cover Page Interactive Data File formatted in inline XBRL

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  CANNAPHARMARX, INC.
   
  By:  /s/ Dominic Colvin
    Dominic Colvin
Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 2 

 

1 Year Cannapharmarx (PK) Chart

1 Year Cannapharmarx (PK) Chart

1 Month Cannapharmarx (PK) Chart

1 Month Cannapharmarx (PK) Chart

Your Recent History

Delayed Upgrade Clock